Future directions could involve investigating the predictive ability of NLR/Hb ratio in larger and more diverse patient populations, as well as exploring its utility in specific disease groups such as pneumonia or pyelonephritis, and also in groups of patients with specific comorbidity such as hypertension or diabetes. Here, GSTM1 is linked to pyelonephritis.